GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Fermenta Biotech Ltd

Fermenta Biotech H1 FY27 Consolidated Revenue down 7% YoY to INR 261.9 crore

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 05 Nov 2026, 01:48 PM IST  ·  BSE ID: c92d8343-eda5-4aa6-9319-f2aaf9e7a462
View Original BSE Filing (PDF)
💡
In Simple Terms
Fermenta Biotech's half-year revenue dropped 7% to INR 261.9 crore, primarily due to lower animal nutrition sales.
🤖 AI Summary
  • Fermenta Biotech reported H1 FY27 consolidated revenue of INR 261.9 crore, down 7% year-on-year.
  • Consolidated EBITDA for H1 FY27 decreased 34% YoY to INR 45.6 crore.
  • Profit after Tax for H1 FY27 was INR 18.9 crore, a 52% decline year-on-year.
  • Human Nutrition revenue increased 2% to INR 162.5 crore; Animal Nutrition revenue fell 52% to INR 22.1 crore.
  • India's business contribution to consolidated revenue increased to 51% in H1 FY27 from 40% a year earlier.
🔢 Key Numbers - exact figures from BSE filing, not rounded
H1 FY27 Consolidated Revenue
INR 261.9 crore
-7%
H1 FY27 Consolidated EBITDA
INR 45.6 crore
-34%
H1 FY27 Consolidated Profit after Tax
INR 18.9 crore
-52%
H1 FY27 Vitamin D3 – Human Nutrition Revenue
INR 162.5 crore
+2%
H1 FY27 Vitamin D3 – Animal Nutrition Revenue
INR 22.1 crore
-52%
H1 FY27 India Revenue Contribution
51%
+11%
Q2 FY27 Consolidated Revenue
INR 135.8 crore
+0.1%
Q2 FY27 Consolidated EBITDA
INR 23.2 crore
-28%
Q2 FY27 Consolidated Profit after Tax
INR 9.4 crore
-48%
🏢 How This Affects the Company
📈
Business Impact
The shift in revenue mix indicates a conscious de-emphasis on the animal nutrition segment due to lower prices, while the human nutrition segment has grown its revenue share to nearly two-thirds.
💰
Financial Impact
Consolidated revenue, EBITDA, and Profit after Tax all experienced year-on-year declines, with EBITDA down 34% and PAT down 52%, partly influenced by one-off income in the prior year's base period.
⚙️
Operational Impact
The company reduced volumes in the animal nutrition segment by 31% YoY and in the human nutrition segment by 13% YoY, suggesting adjusted production or sales strategies.
⚠️
Risk Impact
The significant decrease in animal nutrition segment sales and profitability, coupled with declines in German and US subsidiary revenues, highlights concentration risks in specific business lines and geographies.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which showed a 52% YoY decrease in Profit after Tax to INR 18.9 crore for H1 FY27.
🔍
Management Signal
Management is strategically focusing on building steadier markets, particularly human nutrition and the India business, while de-emphasizing animal nutrition amid its price cycle.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check revenue and profitability trends, especially in human nutrition.
Update on Calcifediol regulatory approvals by end of FY27.
Progress on VITADEE Green® capacities availability from Q2 FY28.
MEDIUM RISK Significant year-on-year declines in revenue, EBITDA, and PAT, alongside falling animal nutrition prices, signal business volatility.
💡 Investor Takeaway
Fermenta Biotech's H1 FY27 consolidated revenue decreased 7% YoY to INR 261.9 crore, with Profit after Tax down 52% to INR 18.9 crore. The decline is attributed to lower animal nutrition prices and non-recurring income in the prior year. Human Nutrition's revenue share grew, and India's business contribution rose to 51%.
⚖️ Strengths & Concerns

✅ Positives

  • Human Nutrition segment revenue grew by 2% to INR 162.5 crore in H1 FY27 despite a 13% YoY volume reduction.
  • India's business contribution increased to 51% of consolidated revenue in H1 FY27 from 40% a year earlier.

⚠️ Concerns

  • Consolidated Profit after Tax for H1 FY27 decreased by 52% YoY to INR 18.9 crore, influenced by lower animal nutrition business and one-off income in the prior year.
  • Vitamin D3 – Animal Nutrition revenue declined 52% YoY to INR 22.1 crore in H1 FY27 due to lower prices and sales volumes.
📅 Company Track Record
Previous filings indicated Fermenta Biotech reported Q2 FY27 standalone net profit of INR 1,395.36 lakhs and its Board met on August 11, 2026, to approve Q1 FY27 financial results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Fermenta Biotech's consolidated revenue for H1 FY27?
Fermenta Biotech's consolidated revenue for H1 FY27 was INR 261.9 crore, which is a 7% decrease year-on-year.
How did Fermenta Biotech's profit after tax perform in H1 FY27?
The consolidated Profit after Tax for Fermenta Biotech in H1 FY27 was INR 18.9 crore, reflecting a 52% decline year-on-year.
What was the performance of Fermenta Biotech's Human Nutrition segment in H1 FY27?
The Human Nutrition segment revenue grew by 2% to INR 162.5 crore in H1 FY27, despite a 13% year-on-year reduction in volumes.
What was the main reason for the decline in Fermenta Biotech's H1 FY27 results?
The decline in H1 FY27 results was primarily due to lower animal nutrition business volumes and pricing, along with prior year EBITDA benefiting from one-off income like insurance and foreign exchange gains.
What is the share of India's business contribution to Fermenta Biotech's consolidated revenue in H1 FY27?
India's business contribution has risen to 51% of Fermenta Biotech's consolidated revenue in H1 FY27, up from 40% a year earlier.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.